Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can give you multiple that have not, I should know I hold many
Totally disagree, lots never rallied, biotech for a start.
Not going to happen, just attempt by the 2 on the board who want this down to $2.75 to buy.
I spoke with IR last week, my opinion is that they are going to provide detailed update early in new year, with possibly a PR anytime with minor update.
Other than that we are low float, low market cap,no debt with increasing revenue company. If other want to chase companies that are no where near as strong as RXMD then so be it.
Only thing holding this back is details of a plan, and I believe we’ll certainly IR is aware of that.
AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.
The deal is AbbVie's second major acquisition announced in the last two weeks, after the pharmaceutical giant announced Nov. 30 it would acquire ImmunoGen for $10 billion.
Cerevel is currently developing potential candidates to treat schizophrenia, Parkinson's disease and mood disorders.
We have seen news last 2 weeks, I expect to see more early next week.
I did just speak with IR regarding recent PR’s. Just my opinion but it is all about increasing sales within the core business which in turn leads to other services that can be offered.
I also believe that they may have more information along the same lines in the coming weeks.
I think it’s important to remember that retail pharmacy is the core business, growth is in the services section of the business which will drive profits up which we are beginning to see each Q.
It’s the start of news, but you don’t want news.
News out;
MIAMI, Nov. 20, 2023 /PRNewswire/ -- Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today announced that its PharmcoRx ("PharmcoRx") pharmacies in Florida will expand their ability to provide customers with access to over-the-counter ("OTC") benefits through a new partnership with NationsBenefits LLC. ("NationsBenefits) for its NationsOTC program.
No you are not, you fail to acknowledge the strides company has made.
I do both and acknowledge what they have achieved but also agree they need to be more vocal and update shareholders.
Company has made a lot of progress and share price will follow.
Cabin if you were that worried you would call the company and speak with Mike, rather than following Capt who has his own agenda.
When I spoke with Mike, he said to me to let people know that he is available to talk with shareholders at anytime, maybe you will get the answers you seek.
Believe me Cabin they know.
I think you know who I was directing that comment too.
No worries if some would just pick up the phone and call IR. I did a few weeks back as I was not happy with lack of communication. That’s my only issue with company, other than that they have done a pretty good job at cleaning up toxic debt, increasing revenue and most importantly profit margins.
I just want to know what their plan is for the cash. I was told as I previously posted that they are aware that they have been quiet on news front but after Q results were out they would be more forthcoming with updates. So we shall see.
My impression from my discussion with IR, is that they are fully aware that they need to provide more information to shareholders and that once Q results were out they would provide updates more frequently.
My opinion is that there should be more news within the next few weeks.
Thanks Stock, maybe a sign they are going to be more open and start communicating more.
You can hold me to it, expecting something by month end. We shall see.
Not going to happen, we get updates soon.
Actually achieved a lot since taking over;
Third Quarter 2023 Financial Highlights:
? Total revenues increased by approximately $2.2 million, or 22%, to approximately $12.4 million during the three months ended September 30, 2023, compared to approximately $10.1 million in the prior year period. Sequentially, total revenues increased by approximately 7% over revenue reported for the second quarter of 2023.
? Prescription revenue, net of PBM fees, increased by approximately $1.1 million, or 13%, to approximately $9.9 million during the third quarter of 2023, compared to approximately $8.8 million in the prior year period.
? 340B contract revenue was approximately $2.5 million during the third quarter of 2023, an increase of approximately $1.3 million, compared to approximately $1.2 million in the prior year period. The increase was attributable to an increase in our existing 340B contracts.
? Gross profit margin increased to approximately 31% from approximately 21% reported in the third quarter of 2022.
? Cash balance as of September 30, 2023 was approximately $7.0 million as compared to approximately $6.7 million as of December 31, 2022.
Now that Q report is out the way, it’s my opinion that company will start communicating with shareholders soon.
Ok thanks, bit confusing with both out.
Yes lots of accounting rules going on in the background, but RXMD cash in bank again increased, not as much as I thought but it keeps on growing.
If you are reading that from NXPL filing then take into account you now have 2 companies salaries.
Not sure what there is not to like in Q report today. Yes there is a lot of financial stuff going on in the background due to NextPlat stake, but revenue up, profit margin up, cash in the bank up and no debt.
Well at least you acknowledge we have had record breaking Q results.
I do agree with you that the company needs to be a lot more vocal and let shareholders know what it plans to do with all that cash. I expect to see over 8 million in the bank this Q.
Funny that as I got a response from IR very quickly and set a time to speak.
For RXMD, and hoping for some clarity on future plans
NXPL on the move today.
Expecting record Q results next week.
I would think so, lots of cash, no need to raise any money anytime soon and low share count.
Certainly not all sectors, maybe large cap.
Not sure how, small caps especially biotech are way down.
He only comments on down days
What you expecting to see for Q results
RemSleep Holdings Inc. (OTCQB:RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, is pleased to announce its DeltaWave mask has moved to the Substantive Review portion of the FDA 510k review process.
Previously, the company voluntarily withdrew its 510k submission during the Acceptance Review portion after meeting with the FDA reviewer. The comments from the reviewer at the time led RemSleep to change its 510k consultant and hire the current one who substantially altered the testing and administration protocol to address issues identified by the reviewer. The proposed regimen was further influenced by her extensive experience in regulatory review with respiratory masks. The current FDA reviewer is the same individual who was assigned to the previous submission.
Holding CEO accountable is by contacting company and dealing with it there, not bashing the company on this board day in and day out. You need to get a life.
I agree but it’s moving in the right direction. Margins have been Improving as there has been more effort to increase higher margin entities within the company. My point is some want to concentrate on the negatives when there are a lot of positives that have taken place over the past year. This Q results should continue to show a trend of profitability and cash growth.
Fundamentally there is absolutely nothing wrong with RMXD, the company is growing, profits are growing, cash in bank is growing and at some point this will reflect in share price.
Our 2 downers on this board would like all to think that the company is in dire strates when in fact it’s complete opposite and probably in best financial health it’s been in.
The only thing that’s keeping this down is lack of communication from the company, and the only thing I can agree on with the 2.
Very much looking forward to Q report where I believe we show Q profit, solid growth, increased margins, more cash in the bank and increased communication from the company.
“We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”
Maybe, maybe not all I want to see is that company is moving in right direction and that revs increase especially in the more profitable side of the business. This Q will be profitable and cash on hand will increase, I just want to know what company has planned for the cash.